Full Press Release Details
Pharmaceuticals Reports SECOND quarter financial results and provides business update
LUMPUR, MALAYSIA, August 13, 2025 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"),
a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business
of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include:
Quarter 2025 Financial Results
of June 30, 2025, cash and cash equivalents totaled $4.3 million, compared to $3.2 million as of December 31, 2024.
cash used in operating activities was $1.1 million for the three months ended June 30, 2025. The Company estimates that its current cash
resources will fund planned expenditure into the fourth quarter of 2025.
and development expenses were $0.1 million for the three months ended June 30, 2025, as compared to $2.0 million for the same period
in 2024. Expenditure for the transcriptional regulation program ceased as a result of the Company's UK subsidiary, Cyclacel Limited,
being liquidated on January 24, 2025. Research and development expenses relating to plogosertib decreased by $0.4 million relative to
the respective comparative period whilst we continue to explore and develop an alternative salt, oral formulation with improved bioavailability.
and administrative expenses decreased by approximately $0.4 million from $1.6 million for the three months ended June 30, 2024 to $1.2
million for the three months ended June 30, 2025, due to lower operating costs of the company under current management. Savings for the
quarter against prior year were $0.9M, but off-set by one-off legacy severance costs and increased legal fees.
other income (expenses), net, for the three months ended June 30, 2025, were broadly flat year on year.
Kingdom research & development tax credits for the three months ended June 30, 2024, were $0.4 million. There were no research and
development tax credits for the three months ended June 30, 2025, following the liquidation of the UK subsidiary and the subsequent loss
of eligibility for recoverable tax credits as a result thereof.
loss for the three months ended June 30, 2025, was $1.3 million (including stock-based compensation expense of $7,000), compared to $3.3
million (including stock-based compensation expense of $0.2 million) for the same period in 2024.
Cyclacel Pharmaceuticals, Inc.
a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology.
The epigenetic/anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological
malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel
drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking
statements include, among other things, statements related to the efficacy and safety profile of fadraciclib in an incomplete clinical
trial, Cyclacel's future plans and prospects, Cyclacel's anticipated cash runway and the planned timing of data results and
continued development of fadraciclib . Factors that may cause actual results to differ materially include market and other conditions,
the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy
in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market
its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with
reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel's
ability to regain and maintain compliance with Nasdaq's continued listing requirements, although no assurance to that effect can
be given. You are urged to consider statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast," "designed,"
"goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list
and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other
periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.
Pharmaceuticals, Inc.
Dr. Doris Wong Sing Ee
Pharmaceuticals, Inc.
PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)
$000s, except share and per share amounts)
| Three Months Ended | ||||||||
| June 30, | ||||||||
| 2025 | 2024 | |||||||
| Revenues: | ||||||||
| Clinical trial supply | - | 4 | ||||||
| Revenues | $ | - | $ | 4 | ||||
| Operating expenses: | ||||||||
| Research and development | 68 | 2,023 | ||||||
| General and administrative | 1,249 | 1,625 | ||||||
| Total operating expenses | 1,317 | 3,648 | ||||||
| Operating loss | (1,317 | ) | (3,644 | ) | ||||
| Other income (expense): | ||||||||
| Foreign exchange gains (losses) | (3 | ) | 3 | |||||
| Interest income | 2 | (28 | ) | |||||
| Other income, net | 2 | - | ||||||
| Total other income (expense), net | 1 | (25 | ) | |||||
| Loss before taxes | (1,316 | ) | (3,669 | ) | ||||
| Income tax benefit | (2 | ) | 412 | |||||
| Net loss | (1,318 | ) | (3,257 | ) | ||||
| Dividend on convertible exchangeable preferred shares | (20 | ) | - | |||||
| Net loss applicable to common shareholders | $ | (1,338 | ) | $ | (3,257 | ) | ||
| Basic and diluted earnings per common share: | ||||||||
| Net loss per share - basic and diluted (common shareholders) | $ | (0.98 | ) | $ | (172.18 | ) |
PHARMACEUTICALS, INC.
$000s, except share, per share, and liquidation preference amounts)
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,275 | $ | 3,137 | ||||
| Prepaid expenses and other current assets | 108 | 537 | ||||||
| Total current assets | 4,383 | 3,674 | ||||||
| Property and equipment, net | 1 | 3 | ||||||
| Right-of-use lease asset | 17 | 5 | ||||||
| Non-current deposits | - | 412 | ||||||
| Total assets | $ | 4,401 | $ | 4,094 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 221 | $ | 4,599 | ||||
| Accrued and other current liabilities | 539 | 1,669 | ||||||
| Total current liabilities | 760 | 6,268 | ||||||
| Lease liability | 10 | - | ||||||
| Total liabilities | 770 | 6,268 | ||||||
| Stockholders' equity | 3,631 | (2,174 | ) | |||||
| Total liabilities and stockholders' equity | $ | 4,401 | $ | 4,094 |